Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Breyanzi
Synonyms :
lisocabtagene maraleucel
Class :
CAR-T Cell Therapies
Brand Name :
Breyanzi
Synonyms :
lisocabtagene maraleucel
Class :
CAR-T Cell Therapies
Dosage Forms & Strengths Â
Injection-suspension Â
70 million cells (1 ea)  Â
Single dose contains 50-110 x 106
Safety and efficacy not establishedÂ
Refer to adult dosingÂ
may have an increasingly adverse effect when combined with car-t cell immunotherapy
may have an increasingly adverse effect when combined with car-t cell immunotherapy
may have an increasingly adverse effect when combined with car-t cell immunotherapy
may have an increasingly adverse effect when combined with car-t cell immunotherapy
may have an increasingly adverse effect when combined with car-t cell immunotherapy
It may enhance the immunosuppressive effects when combined with risankizumab
clofarabine and lisocabtagene maraleucel increase the effect of each other by immunosuppression
By immunosuppressive effects, the effects of the other drug increases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when melphalan is combined with lisocabtagene maraleucel, the risk or severity of adverse effects can be increased
when both the drugs combine the effect of both drugs increases by immunosuppressive effects
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection    
increases the risk of serious infection due to immunosuppression
interaction raises immunosuppressive effects and risk of infection
either of the drug in combination increases the effect of the other due to immunosuppression/risk of infection
increase immunosuppressive effects and risk of infection
increase immunosuppressive effects and risk of infection
either of the drug in combination increases the effect of the other due to immunosuppression/risk of infection
when both drugs are combined, there may be an increased risk of infection Â
when both drugs are combined, there may be an increased risk of adverse effects 
may increase the immunosuppressive effects of each other
Immunosuppressive effects enhance the other's impact and infection risk
immunosuppressive effects enhance the other's impact and infection risk
Frequency Defined Â
>10% Â
Cytokine release syndrome (46%)  Â
Nausea (33%) Â
Musculoskeletal pain (37%)  Â
Hypogammaglobulinemia (32%)  Â
Encephalopathy (29%) Â
Headache (30%) Â
Fatigue (48%) Â
Decreased appetite (28%) Â
Infections (29%)  Â
Diarrhea (26%) Â
Tachycardia (25%) Â
Hypotension (26%)  Â
Dizziness (24%) Â
Cough (23%) Â
Constipation (23%) Â
Vomiting (21%) Â
Abdominal pain (21%)  Â
Edema (21%)  Â
Fever (16%) Â
Tremor (16%) Â
Dyspnea (16%)  Â
Hypertension (14%) Â
Insomnia (14%)  Â
 Â
Pregnancy warnings:    Â
US FDA pregnancy category: N/AÂ
Lactation:  Â
Excreted into human milk is unknown Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.   Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.    Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.    Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: lisocabtagene maraleucel Â
Why do we use lisocabtagene maraleucel?Â
lisocabtagene maraleucel (also known as liso-cel) is a CAR-T cell therapy that is being developed for the treatment of certain types of lymphoma and leukemia. lisocabtagene maraleucel specifically targets the CD19 antigen, which is expressed on the surface of B cells (a type of immune cell). It is being investigated for the treatment of certain types of lymphoma and leukemia, including follicular lymphoma (FL), primary mediastinal large B-cell lymphoma (PMBCL), and diffuse large B-cell lymphoma (DLBCL).Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
